Mymetics vs. malaria
Epalinges – Swiss Mymetics S.A. has sucessfully completed Phase Ib testing of its promising malaria vaccine candidate, which targets both the liver (sporozoite) and the blood form (merozoite) of the malaria parasite Plasmodium falciparum. The vaccine was tolerated well by 40 volunteers, with no discernible safety issues and an observed high sero-conversion rate. The new drug induced a long-lasting antibody response in 70% of the subjects on day 180 against the AMA-1 antigen, which controls merozoite invasion of red blood cells (see p. 44). Additionally, 83 % of the volunteers responded to the CSP-1 antigen (against the sporozoite) on day 365 after two injections. The study, which was performed in collaboration with the Swiss Tropical and Public Health Institute (Swiss TPH) and Pevion Biotech Ltd at the Bagamoyo Research & Training Centre in Tanzania, lays the basis for clinical Phase II development of the vaccine candidate.